Supernus Pharmaceuticals Net Change in Intangible Assets 2011-2024 | SUPN
Supernus Pharmaceuticals net change in intangible assets from 2011 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Supernus Pharmaceuticals Annual Net Change in Intangible Assets
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$-19 |
| 2015 |
$-11 |
| 2014 |
$-2 |
| 2013 |
$N/A |
| 2012 |
$0 |
| 2011 |
$0 |
| 2010 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.819B |
$0.662B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
